Selected research
Market Structure
Global Obstetrics and Gynecology Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Obstetrics and Gynecology Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Obstetrics and Gynecology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Obstetrics and Gynecology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Obstetrics and Gynecology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Obstetrics and Gynecology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Obstetrics and Gynecology Drugs include Abbott, Johnson & Johnson, Novartis, Merck, Roche, Eli Lilly, Pfizer, Bayer and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Obstetrics and Gynecology Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Obstetrics and Gynecology Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Obstetrics and Gynecology Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Obstetrics and Gynecology Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Obstetrics and Gynecology Drugs Segment by Company
Abbott
Johnson & Johnson
Novartis
Merck
Roche
Eli Lilly
Pfizer
Bayer
Amgen
Abbvie
AstraZeneca
TherapeuticsMD
Lupin
GlaxoSmithKline
Ferring
Obstetrics and Gynecology Drugs Segment by Type
Hormonal Therapy
Non-Hormonal Therapy
Obstetrics and Gynecology Drugs Segment by Application
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Obstetrics and Gynecology Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Obstetrics and Gynecology Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Obstetrics and Gynecology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Obstetrics and Gynecology Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Obstetrics and Gynecology Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Obstetrics and Gynecology Drugs industry.
Chapter 3: Detailed analysis of Obstetrics and Gynecology Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Obstetrics and Gynecology Drugsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Hormonal Therapy
- Non-Hormonal Therapy
Applications
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Companies covered
- Abbott
- Johnson & Johnson
- Novartis
- Merck
- Roche
- Eli Lilly
- Pfizer
- Bayer
- Amgen
- Abbvie
- AstraZeneca
- TherapeuticsMD
- Lupin
- GlaxoSmithKline
- Ferring
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Obstetrics and Gynecology Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Hormonal Therapy
- 1.2.3 Non-Hormonal Therapy
- 1.3 Market Analysis by Application
- 1.3.1 Global Obstetrics and Gynecology Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Hospital Pharmacies
- 1.3.3 Online Pharmacies
- 1.3.4 Retail Pharmacies
- 1.4 Global Market Growth Prospects
- 1.5 Global Obstetrics and Gynecology Drugs Growth Trends by Region
- 1.5.1 Global Obstetrics and Gynecology Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Obstetrics and Gynecology Drugs Market Size by Region (2021-2026)
- 1.5.3 Obstetrics and Gynecology Drugs Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Obstetrics and Gynecology Drugs Market Dynamics
- 2.1 Obstetrics and Gynecology Drugs Industry Trends
- 2.2 Obstetrics and Gynecology Drugs Industry Drivers
- 2.3 Obstetrics and Gynecology Drugs Industry Opportunities and Challenges
- 2.4 Obstetrics and Gynecology Drugs Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Obstetrics and Gynecology Drugs Revenue by Company (2021-2026)
- 3.2 Global Obstetrics and Gynecology Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Obstetrics and Gynecology Drugs Key Company Head office and Area Served
- 3.4 Global Obstetrics and Gynecology Drugs Company, Product Type & Application
- 3.5 Global Obstetrics and Gynecology Drugs Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Obstetrics and Gynecology Drugs Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Obstetrics and Gynecology Drugs Players Market Share by Revenue in 2025
- 3.6.3 2025 Obstetrics and Gynecology Drugs Tier 1, Tier 2, and Tier 3
4 Obstetrics and Gynecology Drugs Market by Type
- 4.1 Global Obstetrics and Gynecology Drugs Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Obstetrics and Gynecology Drugs Market Size by Type (2021-2032)
- 4.3 Global Obstetrics and Gynecology Drugs Market Size Share by Type (2021-2032)
5 Obstetrics and Gynecology Drugs Market by Application
- 5.1 Global Obstetrics and Gynecology Drugs Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Obstetrics and Gynecology Drugs Market Size by Application (2021-2032)
- 5.3 Global Obstetrics and Gynecology Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Abbott
- 6.1.1 Abbott Company Information
- 6.1.2 Abbott Business Overview
- 6.1.3 Abbott Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Abbott Obstetrics and Gynecology Drugs Product Portfolio
- 6.1.5 Abbott Recent Developments
- 6.2 Johnson & Johnson
- 6.2.1 Johnson & Johnson Company Information
- 6.2.2 Johnson & Johnson Business Overview
- 6.2.3 Johnson & Johnson Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Johnson & Johnson Obstetrics and Gynecology Drugs Product Portfolio
- 6.2.5 Johnson & Johnson Recent Developments
- 6.3 Novartis
- 6.3.1 Novartis Company Information
- 6.3.2 Novartis Business Overview
- 6.3.3 Novartis Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Novartis Obstetrics and Gynecology Drugs Product Portfolio
- 6.3.5 Novartis Recent Developments
- 6.4 Merck
- 6.4.1 Merck Company Information
- 6.4.2 Merck Business Overview
- 6.4.3 Merck Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Merck Obstetrics and Gynecology Drugs Product Portfolio
- 6.4.5 Merck Recent Developments
- 6.5 Roche
- 6.5.1 Roche Company Information
- 6.5.2 Roche Business Overview
- 6.5.3 Roche Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Roche Obstetrics and Gynecology Drugs Product Portfolio
- 6.5.5 Roche Recent Developments
- 6.6 Eli Lilly
- 6.6.1 Eli Lilly Company Information
- 6.6.2 Eli Lilly Business Overview
- 6.6.3 Eli Lilly Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Eli Lilly Obstetrics and Gynecology Drugs Product Portfolio
- 6.6.5 Eli Lilly Recent Developments
- 6.7 Pfizer
- 6.7.1 Pfizer Company Information
- 6.7.2 Pfizer Business Overview
- 6.7.3 Pfizer Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Pfizer Obstetrics and Gynecology Drugs Product Portfolio
- 6.7.5 Pfizer Recent Developments
- 6.8 Bayer
- 6.8.1 Bayer Company Information
- 6.8.2 Bayer Business Overview
- 6.8.3 Bayer Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Bayer Obstetrics and Gynecology Drugs Product Portfolio
- 6.8.5 Bayer Recent Developments
- 6.9 Amgen
- 6.9.1 Amgen Company Information
- 6.9.2 Amgen Business Overview
- 6.9.3 Amgen Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Amgen Obstetrics and Gynecology Drugs Product Portfolio
- 6.9.5 Amgen Recent Developments
- 6.10 Abbvie
- 6.10.1 Abbvie Company Information
- 6.10.2 Abbvie Business Overview
- 6.10.3 Abbvie Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Abbvie Obstetrics and Gynecology Drugs Product Portfolio
- 6.10.5 Abbvie Recent Developments
- 6.11 AstraZeneca
- 6.11.1 AstraZeneca Company Information
- 6.11.2 AstraZeneca Business Overview
- 6.11.3 AstraZeneca Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 AstraZeneca Obstetrics and Gynecology Drugs Product Portfolio
- 6.11.5 AstraZeneca Recent Developments
- 6.12 TherapeuticsMD
- 6.12.1 TherapeuticsMD Company Information
- 6.12.2 TherapeuticsMD Business Overview
- 6.12.3 TherapeuticsMD Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 TherapeuticsMD Obstetrics and Gynecology Drugs Product Portfolio
- 6.12.5 TherapeuticsMD Recent Developments
- 6.13 Lupin
- 6.13.1 Lupin Company Information
- 6.13.2 Lupin Business Overview
- 6.13.3 Lupin Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Lupin Obstetrics and Gynecology Drugs Product Portfolio
- 6.13.5 Lupin Recent Developments
- 6.14 GlaxoSmithKline
- 6.14.1 GlaxoSmithKline Company Information
- 6.14.2 GlaxoSmithKline Business Overview
- 6.14.3 GlaxoSmithKline Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 GlaxoSmithKline Obstetrics and Gynecology Drugs Product Portfolio
- 6.14.5 GlaxoSmithKline Recent Developments
- 6.15 Ferring
- 6.15.1 Ferring Company Information
- 6.15.2 Ferring Business Overview
- 6.15.3 Ferring Obstetrics and Gynecology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Ferring Obstetrics and Gynecology Drugs Product Portfolio
- 6.15.5 Ferring Recent Developments
7 North America
- 7.1 North America Obstetrics and Gynecology Drugs Market Size (2021-2032)
- 7.2 North America Obstetrics and Gynecology Drugs Market Size by Type
- 7.2.1 North America Obstetrics and Gynecology Drugs Market Size by Type (2021-2026)
- 7.2.2 North America Obstetrics and Gynecology Drugs Market Size by Type (2027-2032)
- 7.2.3 North America Obstetrics and Gynecology Drugs Market Share by Type (2021-2032)
- 7.3 North America Obstetrics and Gynecology Drugs Market Size by Application
- 7.3.1 North America Obstetrics and Gynecology Drugs Market Size by Application (2021-2026)
- 7.3.2 North America Obstetrics and Gynecology Drugs Market Size by Application (2027-2032)
- 7.3.3 North America Obstetrics and Gynecology Drugs Market Share by Application (2021-2032)
- 7.4 North America Obstetrics and Gynecology Drugs Market Size by Country
- 7.4.1 North America Obstetrics and Gynecology Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Obstetrics and Gynecology Drugs Market Size by Country (2021-2026)
- 7.4.3 North America Obstetrics and Gynecology Drugs Market Size by Country (2027-2032)
- 7.4.4 North America Obstetrics and Gynecology Drugs Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Obstetrics and Gynecology Drugs Market Size (2021-2032)
- 8.2 Europe Obstetrics and Gynecology Drugs Market Size by Type
- 8.2.1 Europe Obstetrics and Gynecology Drugs Market Size by Type (2021-2026)
- 8.2.2 Europe Obstetrics and Gynecology Drugs Market Size by Type (2027-2032)
- 8.2.3 Europe Obstetrics and Gynecology Drugs Market Share by Type (2021-2032)
- 8.3 Europe Obstetrics and Gynecology Drugs Market Size by Application
- 8.3.1 Europe Obstetrics and Gynecology Drugs Market Size by Application (2021-2026)
- 8.3.2 Europe Obstetrics and Gynecology Drugs Market Size by Application (2027-2032)
- 8.3.3 Europe Obstetrics and Gynecology Drugs Market Share by Application (2021-2032)
- 8.4 Europe Obstetrics and Gynecology Drugs Market Size by Country
- 8.4.1 Europe Obstetrics and Gynecology Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Obstetrics and Gynecology Drugs Market Size by Country (2021-2026)
- 8.4.3 Europe Obstetrics and Gynecology Drugs Market Size by Country (2027-2032)
- 8.4.4 Europe Obstetrics and Gynecology Drugs Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Obstetrics and Gynecology Drugs Market Size (2021-2032)
- 9.2 China Obstetrics and Gynecology Drugs Market Size by Type
- 9.2.1 China Obstetrics and Gynecology Drugs Market Size by Type (2021-2026)
- 9.2.2 China Obstetrics and Gynecology Drugs Market Size by Type (2027-2032)
- 9.2.3 China Obstetrics and Gynecology Drugs Market Share by Type (2021-2032)
- 9.3 China Obstetrics and Gynecology Drugs Market Size by Application
- 9.3.1 China Obstetrics and Gynecology Drugs Market Size by Application (2021-2026)
- 9.3.2 China Obstetrics and Gynecology Drugs Market Size by Application (2027-2032)
- 9.3.3 China Obstetrics and Gynecology Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Obstetrics and Gynecology Drugs Market Size (2021-2032)
- 10.2 Asia Obstetrics and Gynecology Drugs Market Size by Type
- 10.2.1 Asia Obstetrics and Gynecology Drugs Market Size by Type (2021-2026)
- 10.2.2 Asia Obstetrics and Gynecology Drugs Market Size by Type (2027-2032)
- 10.2.3 Asia Obstetrics and Gynecology Drugs Market Share by Type (2021-2032)
- 10.3 Asia Obstetrics and Gynecology Drugs Market Size by Application
- 10.3.1 Asia Obstetrics and Gynecology Drugs Market Size by Application (2021-2026)
- 10.3.2 Asia Obstetrics and Gynecology Drugs Market Size by Application (2027-2032)
- 10.3.3 Asia Obstetrics and Gynecology Drugs Market Share by Application (2021-2032)
- 10.4 Asia Obstetrics and Gynecology Drugs Market Size by Country
- 10.4.1 Asia Obstetrics and Gynecology Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Obstetrics and Gynecology Drugs Market Size by Country (2021-2026)
- 10.4.3 Asia Obstetrics and Gynecology Drugs Market Size by Country (2027-2032)
- 10.4.4 Asia Obstetrics and Gynecology Drugs Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Obstetrics and Gynecology Drugs Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Obstetrics and Gynecology Drugs Market Size by Type
- 11.2.1 South America, Middle East & Africa Obstetrics and Gynecology Drugs Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Obstetrics and Gynecology Drugs Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Obstetrics and Gynecology Drugs Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Obstetrics and Gynecology Drugs Market Size by Application
- 11.3.1 South America, Middle East & Africa Obstetrics and Gynecology Drugs Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Obstetrics and Gynecology Drugs Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Obstetrics and Gynecology Drugs Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Obstetrics and Gynecology Drugs Market Size by Country
- 11.4.1 South America, Middle East & Africa Obstetrics and Gynecology Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Obstetrics and Gynecology Drugs Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Obstetrics and Gynecology Drugs Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Obstetrics and Gynecology Drugs Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst